DOTATOC PET/CT for Imaging NET Patients

Summary

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventional imaging are used to detect NETs.

This study proposes 68Gallium(68Ga)-DOTATOC positron emission tomography/computed tomography (PET/CT) is superior to current imaging techniques. The goal is to evaluate the safety and sensitivity of 68Ga-DOTATOC PET/CT at detecting NETs and other tumors with over-expression of somatostatin receptors.

Conditions

• Ganglioneuroma
• Neuroendocrine Tumors
• Insulinoma
• Gastrinoma
• Glucagonoma
• Vipoma
• Pheochromocytoma
• Paraganglioma
• Neuroblastoma
• Medullary Carcinoma
• Pituitary Adenoma
• Medulloblastoma
• Merkel Cell Carcinoma
• Small-cell Lung Cancer
• Meningioma
• Carcinoid

Interventions

DIAGNOSTIC_TEST

68Ga-DOTATOC PET/CT

Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

DIAGNOSTIC_TEST

18F-FDG PET/CT

18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

Sponsors & Collaborators

• British Columbia Cancer Agency

  lead OTHER

Principal Investigators

• Francois Benard, MD · BC Cancer

Eligibility

Min Age

18 Years

Max Age

100 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-07-11

Primary Completion

2026-09-30

Completion

2028-09-30

Countries

• Canada

Study Locations